Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.42 |
| ▸ | S100A9 | P06702 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 12/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.40 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3797045 | 0.80 | L3MBTL1 (0.47) | IRAK4L3MBTL1 | |
| SCHEMBL1726018 | 0.79 | CCNA2 (0.42) | S100A9IRAK4L3MBTL1 | |
| SCHEMBL16209890 | 0.75 | CYP1A2 (0.54) | L3MBTL1VNN1 | |
| SCHEMBL8989530 | 0.74 | KDM4E (0.40) | S100A9IRAK4L3MBTL1 | |
| SCHEMBL1725102 | 0.73 | IRAK4 (0.42) | IRAK4L3MBTL1 | |
| SCHEMBL1725287 | 0.72 | IRAK4 (0.48) | IRAK4 | |
| SCHEMBL1727254 | 0.72 | KDM4E (0.44) | IRAK4 | |
| SCHEMBL1726524 | 0.71 | IRAK4 (0.44) | IRAK4 | |
| SCHEMBL1173688 | 0.71 | TRPM8 (0.42) | EGLN1S100A9FLT1EGLN3 | |
| SCHEMBL14765568 | 0.71 | DPP4 (0.50) | EGLN1FLT1EGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791142-B2 | Oxazole pyridine derivatives useful as S1P1 receptor agonists | MERCK SERONO S.A. (CH) | 2014-07-29 | — | — | US | disclosed |
| US-20110306636-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | MERCK SERONO SA (CH) | 2011-12-15 | — | — | US | disclosed |
| WO-2010100142-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | MERCK SERONO S.A. (CH) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306636-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR5 | EGLN1 1628/4885S100A9 4028/4885IRAK4 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.